

1 **Declining Opioid Distribution to US Hospitals**

2 Sarah A. Eidbo^{1*}, Amalie K. Kropp Lopez¹, Joseph D. Hagedorn¹, Varkey Mathew¹, Daniel E.
3 Kaufman¹, Kenneth L. McCall², Brian J. Piper¹

4 ¹Geisinger Commonwealth School of Medicine, Scranton, PA, 18509, USA;
5 bpiper@som.geisinger.edu (B.J.P.); seidbo@som.geisinger.edu (S.A.E.);
6 jhagedorn@som.geisinger.edu (J.D.H.); dkaufman01@som.geisinger.edu (D.E.K.);
7 akropplopez@som.geisinger.edu (A.K.K.L.); vmathew@som.geisinger.edu (V.M.)

8 ²University of New England, Portland, ME, 04103, USA; kmccall@une.edu (K.L.M.)

9 Figures: 7, Tables: 0

10 Disclosures: BJP is part of an osteoarthritis research team supported by Pfizer and Eli Lilly. The
11 other authors have no disclosures.

12 *Corresponding author: Sarah Eidbo, Department of Medical Education, Geisinger
13 Commonwealth School of Medicine, 525 Pine Street, Scranton, PA 18509, (814)-573-3686,
14 SEidbo@som.geisinger.edu

15 **ABSTRACT**

16 The United States is enduring a preventable opioid crisis, particularly involving a population
17 specifically being treated in a hospital setting. This project analyzed trends in distribution of
18 opioids by hospitals in the United States from 2000 to 2019. Opioids monitored included
19 buprenorphine, codeine, fentanyl, hydrocodone, hydromorphone, meperidine, methadone,
20 morphine, oxycodone, oxymorphone, powdered opium, remifentanyl, and tapentadol. The
21 Automation of Reports and Consolidated Orders System (ARCOS) reports controlled
22 substances via the Drug Enforcement Administration (DEA). Data from ARCOS reports 5 and 7
23 from 2000 to 2019 were utilized for an observational study on hospital opioid distribution in the
24 US. Morphine milligram equivalents (MME) were calculated using oral conversion factors for
25 each opioid. The MME per person per state was calculated to compare data from the peak year,
26 2012, to data from 2019. Opioid use in the United States peaked in 2012 with a 46.6% decline
27 from 2012 to 2019. Within the US, 25 of 50 states have seen a decrease of 50% or greater. Of
28 the opioid compounds observed, buprenorphine has seen increased (123%) hospital use from
29 2000 to 2019. All other opioids have been experiencing a slow decline (>40%) in hospital use
30 since that time. This study demonstrated the progress made thus far by hospitals in curbing the
31 US opioid epidemic.

32

33 **INTRODUCTION**

34 The United States (US) is currently enduring a persistent opioid crisis with 128 people dying each
35 day from opioid overdoses [1]. The US Department of Health and Human Services estimates that 40% of
36 opioid overdose deaths involve a prescription opioid [2]. Despite the US constituting only 4.4% of the
37 global population, it constituted 30.2% of global opioid consumption [3]. Recent data from the
38 American Hospital Association state that there are currently 6,146 US hospitals with 924,107 staffed
39 beds [4]. In an observational study of opioid exposure and related adverse effects, opioids were utilized
40 in treatment for over half of hospital admissions of nonsurgical patients in 286 US hospitals [5]. Opioids
41 are closely linked with care within the hospital setting. Roughly 50 million surgical procedures a year are
42 performed in the United States. Six percent of patients undergoing minor or major surgery continued
43 opioid use 90 days after surgery, well after the normal scope of post-procedure pain treatment [6].
44 These findings align with the 5% incidence of new long-term opioid use after the first opioid exposure
45 identified by the Oregon prescription drug monitoring program data, which includes non-operative
46 opioid prescriptions [7]. The severe adverse effects that acute and chronic opioid use can cause are also
47 important. Within the inpatient hospital setting, opioids are among the most frequently associated with
48 potentially life-threatening events. Up to 14% of postoperative patients that were prescribed opioids
49 experienced an adverse event. Patients were three times as likely to experience an adverse drug event
50 as someone who was not prescribed opioids [8]. Among 300,000 surgeries, 12.2% of patients
51 experienced an opioid-related adverse event, leading to greater overall costs, longer hospitalizations,
52 and increased likelihood of readmission [9].

53 Despite the prevailing perception that the opioid epidemic is worsening, practitioners and
54 hospitals have taken note of these trends [10]. Steps to hinder the epidemic are already taking effect.
55 Recent hospital initiatives include stewardship programs for better education of prescribers as well as

56 increased efforts to reduce negative outcomes – both aimed at decreasing the risk of opioid-related
57 adverse events [11].

58 This observational study aimed to determine trends in hospital retail distribution of opioids in
59 the US from 2000 to 2019, using the Automation of Reports and Consolidated Orders System (ARCOS).
60 ARCOS is a comprehensive drug reporting system for substances controlled by the Drug Enforcement
61 Administration (DEA), which reports on an array of opioids and opioid derivatives in addition to many
62 other substances and has been examined in prior pharmacoepidemiological reports [12, 13, 14]. Several
63 schedule II and III opioids used for pain control were studied using this database including codeine,
64 oxycodone, hydromorphone, hydrocodone, meperidine, morphine, powdered opium, oxymorphone,
65 remifentanyl, tapentadol, and fentanyl. Two drugs utilized for also opioid use disorder (OUD),
66 buprenorphine and methadone, were also analyzed.

67

68 **METHODS**

69 **Procedures**

70 All data was collected from ARCOS [15] for this observational study. The database is an ongoing
71 reporting system that monitors DEA-controlled substances from their manufacture through their retail
72 distribution to hospitals, pharmacies, practitioners, and teaching institutions, which are collectively
73 grouped under business activities in several reports. Data from reports 5 and 7 were collected for 2000
74 to 2019. Report 5 details the average purchased amount of each drug, for each business activity, in each
75 state. Report 7 gives the average purchased amount of drug for each business activity within the entire
76 United States. The opioids included were buprenorphine, codeine, fentanyl base, hydrocodone,
77 hydromorphone, meperidine, methadone, morphine, oxycodone, oxymorphone, powdered opium, and
78 tapentadol. This study was deemed exempt by the IRBs of the University of New England and Geisinger.

79 **Statistics**

80 The programs GraphPad Prism, Microsoft Excel, and JMP were used to graph and analyze this
81 data. American Community Survey estimates of yearly state populations were used with opioids
82 reported per 100 population [16]. To compare opioids of different formulations, established oral
83 conversion factors were used to calculate the morphine milligram equivalent (MME) of each opioid
84 listed with their corresponding multipliers. Oral conversion factors used were morphine: 1, oxycodone:
85 1.5, fentanyl: 75, hydrocodone: 1, hydromorphone: 4, oxymorphone: 3, tapentadol: 0.4, codeine: 0.15,
86 meperidine: 0.1, methadone: 8, and buprenorphine: 10 [17]. The morphine milligram equivalent is the
87 milligrams of morphine that the amount of opioid would be equivalent to. The percent change was
88 calculated using the MME per person per state to compare 2012, the year with the highest US MME
89 total, to years 2017-2019. State values that were outside a 95 percent confidence interval, calculated as
90 mean +/- 1.96 * Standard Deviation, were considered statistically significant.

91

92 **RESULTS**

93 Due to the evolving nature of the data collected in this study, three separate percent changes
94 were calculated as more recent data was made available by ARCOS. These three percent changes were
95 between 2012 relative to 2017, 2018, and 2019. Hospital opioid use in the United States has seen a
96 31.1% decrease from 2012 to 2017 (Figure 1). When total opioid weights were calculated for the United
97 States by year, the year 2012 had the highest hospital opioid distribution (19,188.91 kg MME). In 2017,
98 the opioid kg MME was 13,227.88 kg MME, resulting in a 31.1% decrease. From 2012 to 2018, hospital
99 opioid use saw a 39.7% decrease (Figure 1). The year 2012 was again used for the highest hospital opioid
100 distribution by total opioid weight, with 19,188.91 kg MME. This was compared with the opioid kg MME
101 of 2018, which was 11,574.61 kg MME. Between 2012 and 2019, hospital opioid use has seen a 46.6%
102 change (Figure 1). When total opioid weights were calculated for the United States by year, 2012 was

103 the year with the highest hospital opioid distribution, with 19,188.91 kg MME. When compared with the
104 MME of 2019, 10,246.95 kg MME, a net decrease of 46.6% was seen.

105 When hospital opioid totals were broken down by their individual opioids, patterns became
106 more apparent (Figure 2). A wide range in distribution weights amongst opioids required that they be
107 separated into three groups. The opioids with the highest hospital distribution were oxycodone,
108 morphine, and hydrocodone, all three of which displayed declining usage over the past several years.
109 The middle group of opioids included codeine, methadone, hydromorphone, meperidine,
110 buprenorphine and tapentadol. These drugs also displayed a steady decline, except for buprenorphine,
111 which had distribution increases, and tapentadol, which rose after coming onto the market and then
112 began to fall in 2017. The group of opioids with the lowest distribution included fentanyl, powdered
113 opium, oxymorphone, and remifentanyl. These drugs all remained steady.

114 Opioids were then organized by their percent change between 2012, the peak year, and 2019
115 (Figure 3). All opioids displayed a percent decrease except for buprenorphine, which had a +123%
116 increase. Six opioids had decreases of 50% or over: hydromorphone (-49.9%), oxymorphone (-57.7%),
117 methadone (-58.7%), morphine (-66.9%), codeine (-67.5%), and meperidine (-77.6%).

118 Hospital opioid distribution was then broken down by state, by the opioid weight distributed per
119 person by each state's population (Figure 4, 5). The average opioid weight distributed per person was
120 17.91 (SD= 6.92) mg. Compared with 2012, several changes are worth noting – firstly, that half of the
121 United States experienced a 50% or greater percent decrease in hospital-distributed opioid weights per
122 person (Figure 7). Secondly, the state with the highest hospital-distributed opioid weight per person in
123 2012 was South Carolina, which has seen a 94% decrease in 2019. The percent decrease that South
124 Carolina experienced was calculated to be an outlier among the states' percent decreases. It is also
125 worth mentioning that in 2019, the states with the highest hospital opioid distribution per person by
126 weight were Alaska, Montana, Colorado, and North Dakota (Figure 5). These have changed from 2012,

127 when the states with the highest distribution were South Carolina, Alaska, North Dakota, and South
128 Dakota (Figure 6). Alaska and North Dakota have remained among the states with the highest hospital
129 opioid distributions by weight per person (Figure 5).

130

131 **DISCUSSION**

132 This study identified the changes in opioid distribution within United States hospitals from 2000
133 to 2019. Many opioid medications have been declining in use since peaking in 2012. Hospital opioid
134 distribution overall has seen a decrease of 46.6% between 2012 and 2019. This comes with the
135 exception of buprenorphine, which has seen a 123% increase in use since 2012, as it is being used to
136 combat opioid use disorder. Other opioid medications observed in this investigation reached their peak
137 distributions in 2011 with declining rates since.

138 The disproportionate amounts of certain opioid medications distributed in some states is
139 another interesting find. In 2012, South Carolina had the largest hospital-distributed opioid weight per
140 person in the country – it was over twice the weight per person of the state with the second highest
141 distributed opioid weight. Further investigation revealed this high weight to be mostly due to codeine
142 and hydrocodone distribution. Other opioid medications appeared to be within a similar range of the
143 distributed weights of other states. Although the reasoning behind the distribution of these two opioid
144 drugs in South Carolina is unclear, it had receded by 2019. South Carolina had a remarkable 94%
145 decrease in hospital-opioid distribution per person, making it 44th in rank for the highest opioid
146 distribution weight.

147 In 2019, Alaska had the highest hospital distribution per person followed by Montana, Colorado,
148 and North Dakota. Within Alaska, the rates of opioid-related inpatient hospitalizations were 28.5 per
149 100,000 persons in 2016 and 26.0 per 100,000 persons in 2017, with total inpatient hospitalization

150 charges exceeding \$23 million [18]. The state is beginning to implement changes to reduce the
151 escalating overdose deaths and high hospitalization rates.

152 The lowest hospital opioid distribution per person in 2019 was seen in New Jersey, followed by
153 Illinois, New York, and Connecticut. In several of these states, guidelines have been implemented that
154 include a multifaceted approach to reducing hospital opioid distribution. These approaches include
155 performing a patient evaluation before prescribing, getting informed consent for opioid treatment, and
156 periodic review of the complete medical record. This comes from state advisory guidelines on use of
157 controlled substances in treatment of intractable pain [19]. The opioid epidemic affects people of all
158 metrics across the nation, but these state-dependent differences indicate that further investigation is
159 necessary for better understanding of this complex crisis.

160 The US is not alone in the observation of this trend over the last two decades. In Canada, one
161 out of five adults reports living with chronic pain. Codeine, oxycodone, and hydromorphone were also
162 the most commonly prescribed opioid medications for pain in Canada. However in a study from 2013 to
163 2016 in Ontario, Saskatchewan and British Columbia, some slight decreases in opioid prescriptions were
164 observed. The investigation revealed that fewer Canadians were being prescribed opioids (8.0% fewer)
165 and fewer citizens are starting opioid therapy as treatment for pain in all age groups (9.6% fewer).
166 Changes were also made to prescribed opioid dosages and durations. In summary, frequency in
167 prescribing opioids for under a week increased and frequency of opioids prescribed for longer than a
168 week declined [20].

169 Hospitals and insurance companies across the US have been searching for methods to decrease
170 the number of opioid medications prescribed to patients. This multifaceted problem must be addressed
171 according to multiple variables. Funding has been allocated to several areas thus far: addiction
172 prevention strategies, programs aimed at identifying individuals at high risk of opioid use and misuse,

173 increasing treatment facility number, and increased efforts of law enforcement agencies [21]. However,
174 despite new safety nets put in place, physicians still balance on a fine line between treating the pain of a
175 patient and potentially over-prescribing these complicated medications.

176 Hospitals in the United States are integrating improved guidelines to reduce amounts of
177 potentially unnecessary opioid prescriptions. A recent report from 81 hospitals found that 98%
178 implemented changes to their opioid delivery practices between July of 2017 and July of 2018. The
179 changes made included improved prescriber education and new technologies to monitor prescribing
180 practices, which limited the dosage and quantities of given opioids [22].

181 Post-surgical opioid use could be a potential gateway to chronic opioid use, if opioid
182 medications are used incorrectly. With the low number of patients taking their prescribed doses of
183 opioid medications after surgery, this suggests that perhaps their pain could be managed via other
184 modalities. Patients' pain can often be controlled with nonsteroidal anti-inflammatory drugs (NSAIDs)
185 and acetaminophen, removing the need for opioids and other stronger pain medications. However, the
186 decision to prescribe a patient NSAIDs and acetaminophen in the place of opioids and other strong pain
187 medications comes down to the healthcare team. The healthcare team's ability to educate patients and
188 create appropriate expectations for home pain management is vital in these situations [23].

189 Certain strengths and weaknesses of this novel dataset should be taken into consideration.
190 ARCOS only reports in the hospital business activity on agents that are sent by distributors to hospitals.
191 Prescriptions that are written within the hospital – such as those following a surgery – but filled in a non-
192 hospital pharmacy are reported by ARCOS as pharmacy-distributed opioids. However, the
193 comprehensive nature of ARCOS makes it an important source for follow-up reports.

194 In conclusion, this study observed the differences and trends of 13 different opioids within
195 hospitals from 2000 to 2019 at a national and state level. These changes support those observed at a

196 national level for all opioid distribution - not just within hospitals. Since 2011, there has been a steady
197 decrease in the distribution of opioids for pain and increases in buprenorphine for opioid use disorder.
198 Hospitals were prescribing less opioids, while also taking steps to make prescribing opioids safer for
199 patients. This is without a doubt a positive step toward combating the effects of the opioid crisis in the
200 US healthcare system.

201 **Acknowledgements**

202 Stephanie Nichols, PharmD provided feedback on an earlier version of this report.

203

204 **References**

- 205 1. Opioid Overdose Crisis. National Institute on Drug Abuse. (2020, June 10). Retrieved October 09,
206 2020, from <https://www.drugabuse.gov/drug-topics/opioids/opioid-overdose-crisis>.
- 207 2. What is the U.S. Opioid Epidemic? U.S. Department of Health and Human Services. (2019,
208 September 04). Retrieved October 03, 2020, from [https://www.hhs.gov/opioids/about-the-](https://www.hhs.gov/opioids/about-the-epidemic/index.html)
209 [epidemic/index.html](https://www.hhs.gov/opioids/about-the-epidemic/index.html)
- 210 3. Indicator Dashboards: Opioid dashboard prescribing practices perception of pain. Minnesota
211 Department of Health. (2020). Retrieved November 03, 2020, from
212 <https://www.health.state.mn.us/communities/opioids/prevention/painperception.html>
- 213 4. Fast Facts on U.S. Hospitals, 2020. American Hospital Association. (2020). Retrieved November
214 03, 2020, from <https://www.aha.org/statistics/fast-facts-us-hospitals>
- 215 5. Herzig SJ, Rothberg MB, Cheung M, Ngo LH, Marcantonio ER. Opioid utilization and opioid-
216 related adverse events in nonsurgical patients in US hospitals. *J Hosp Med*. 2014 Feb;9(2):73-81.
217 doi: 10.1002/jhm.2102. Epub 2013 Nov 13. PMID: 24227700; PMCID: PMC3976956.
- 218 6. Brummett CM, Waljee JF, Goesling J, Moser S, Lin P, Englesbe MJ, Bohnert ASB, Kheterpal S,
219 Nallamothu BK. New persistent opioid use after minor and major surgical procedures in us

- 220 adults. *JAMA Surg.* 2017 Jun 21;152(6):e170504. doi: 10.1001/jamasurg.2017.0504. Epub 2017
221 Jun 21. Erratum in: *JAMA Surg.* 2019 Mar 1;154(3):272. PMID: 28403427; PMCID: PMC7050825.
- 222 7. Deyo RA, Hallvik SE, Hildebran C, Marino M, Dexter E, Irvine JM, O'Kane N, Van Otterloo J,
223 Wright DA, Leichtling G, Millet LM. Association Between initial opioid prescribing patterns and
224 subsequent long-term use among opioid-naïve patients: a statewide retrospective cohort study.
225 *J Gen Intern Med.* 2017 Jan;32(1):21-27. doi: 10.1007/s11606-016-3810-3. Epub 2016 Aug 2.
226 PMID: 27484682; PMCID: PMC5215151.
- 227 8. Davies EC, Green CF, Taylor S, Williamson PR, Mottram DR, Pirmohamed M. Adverse drug
228 reactions in hospital in-patients: a prospective analysis of 3695 patient-episodes. *PLoS One.*
229 2009;4(2):e4439. doi: 10.1371/journal.pone.0004439. Epub 2009 Feb 11. PMID: 19209224;
230 PMCID: PMC2635959.
- 231 9. Oderda GM, Gan TJ, Johnson BH, Robinson SB. Effect of opioid-related adverse events on
232 outcomes in selected surgical patients. *J Pain Palliat Care Pharmacother.* 2013 Mar;27(1):62-70.
233 doi: 10.3109/15360288.2012.751956. Epub 2013 Jan 9. PMID: 23302094.
- 234 10. Goodnough, A. Opioid deaths have surged during the pandemic, C.D.C Data Shows. New York
235 Times, April 14, 2021. [https://www.nytimes.com/2021/04/14/health/overdose-deaths-fentanyl-](https://www.nytimes.com/2021/04/14/health/overdose-deaths-fentanyl-opioids-coronaviurs-pandemic.html?searchResultPosition=3)
236 [opioids-coronaviurs-pandemic.html?searchResultPosition=3](https://www.nytimes.com/2021/04/14/health/overdose-deaths-fentanyl-opioids-coronaviurs-pandemic.html?searchResultPosition=3)
- 237 11. Gallegos, A. (2019, March 15). Hospitals changing practices to curb opioid epidemic. Retrieved
238 November 03, 2020, from [https://acphospitalist.org/archives/2019/03/hospitals-changing-](https://acphospitalist.org/archives/2019/03/hospitals-changing-practices-to-curb-opioid-epidemic.htm)
239 [practices-to-curb-opioid-epidemic.htm](https://acphospitalist.org/archives/2019/03/hospitals-changing-practices-to-curb-opioid-epidemic.htm)
- 240 12. Cabrera FF, Gamarra ER, Garcia TE, Littlejohn AD, Chinga PA, Pinentel-Morillo LD, Tirado JR,
241 Chung DY, Pande LJ, McCall KL, Nichols SD, Piper BJ. Opioid distribution trends (2006-2017) in
242 the US Territories. *PeerJ.* 2019 Jan 15;7:e6272. doi: 10.7717/peerj.6272. PMID: 30671308;
243 PMCID: PMC6338096.

- 244 13. Collins LK, Pande LJ, Chung DY, Nichols SD, McCall KL, Piper BJ. Trends in the medical supply of
245 fentanyl and fentanyl analogues: United States, 2006 to 2017. *Prev Med*. 2019; 123:95-100. doi:
246 10.1016/j.ypmed.2019.02.017.
- 247 14. Davis CS, Piper BJ, Gertner AK, Rotter JS. Opioid prescribing laws are not associated with short-
248 term declines in prescription opioid distribution. *Pain Med*. 2020 Mar 1;21(3):532-537. doi:
249 10.1093/pm/pnz159.
- 250 15. Drug Enforcement Administration, Diversion Control Division. Retrieved from
251 https://www.deadiversion.usdoj.gov/arcos/retail_drug_summary/index.html
- 252 16. American Community Survey (ACS). U.S. Census Bureau. (2020, October 22). Retrieved
253 November 03, 2020, from <https://www.census.gov/programs-surveys/acs>
- 254 17. Piper BJ, Shah DT, Simoyan OM, McCall KL, Nichols SD. Trends in medical use of opioids in the
255 U.S., 2006-2016. *Am J Prev Med* 2018; 54(5):652-660. doi: 10.1016/j.amepre.2018.01.034.
- 256 18. Opioid Epidemic in Alaska. Alaska Department of Health and Social Services. Retrieved
257 November 03, 2020, from <http://dhss.alaska.gov/dph/Director/Pages/opioids/home.aspx>
- 258 19. Davis, C. Appendix B: State-by-state summary of opioid prescribing regulations and guidelines.
259 [https://www.azdhs.gov/documents/prevention/womens-childrens-health/injury-](https://www.azdhs.gov/documents/prevention/womens-childrens-health/injury-prevention/opioid-prevention/appendix-b-state-by-state-summary.pdf)
260 [prevention/opioid-prevention/appendix-b-state-by-state-summary.pdf](https://www.azdhs.gov/documents/prevention/womens-childrens-health/injury-prevention/opioid-prevention/appendix-b-state-by-state-summary.pdf)
- 261 20. Canadian Institute for Health Information. Opioid prescribing in Canada: How are practices
262 changing?. Ottawa, ON: CIHI; 2019.
- 263 21. 340B hospitals on the front lines of addressing the US opioid epidemic: Case examples from the
264 field. (2019, January). Retrieved 2020, from
265 https://www.340bhealth.org/files/OpioidReport_FINAL_1_23_19.pdf

- 266 22. Gallegos, A. (2019, March 15). Hospitals changing practices to curb opioid epidemic. Retrieved
267 November 03, 2020, from [https://acphospitalist.org/archives/2019/03/hospitals-changing-](https://acphospitalist.org/archives/2019/03/hospitals-changing-practices-to-curb-opioid-epidemic.htm)
268 [practices-to-curb-opioid-epidemic.htm](https://acphospitalist.org/archives/2019/03/hospitals-changing-practices-to-curb-opioid-epidemic.htm)
- 269 23. Mark J, Argentieri DM, Gutierrez CA, Morrell K, Eng K, Hutson AD, Mayor P, Szender JB, Starbuck
270 K, Lynam S, Blum B, Akers S, Lele S, Paragh G, Odunsi K, de Leon-Casasola O, Frederick PJ, Zsiros
271 E. Ultrarestrictive opioid prescription protocol for pain management after gynecologic and
272 abdominal surgery. *JAMA Netw Open*. 2018 Dec 7;1(8):e185452. doi:
273 10.1001/jamanetworkopen.2018.5452. PMID: 30646274; PMCID: PMC6324564.
- 274
- 275
- 276

277 **Figure captions:**

278 **Figure 1.** Total opioid distribution in morphine milligram equivalents (MME) in kilograms from 2001 to
279 2019 as reported by the Drug Enforcement Administration's Automated Reports and Consolidated
280 Orders System to hospitals for buprenorphine, codeine, fentanyl, hydrocodone, hydromorphone,
281 meperidine, methadone, morphine, oxycodone, oxymorphone, and tapentadol (black) or with
282 buprenorphine removed (blue).

283 **Figure 2.** Individual opioid weights (kg) distributed to US hospitals as reported by the Drug Enforcement
284 Administration's Automated Reports and Consolidated Ordering System (ARCOS) from 2001 to 2018.
285 The percent change relative to the peak year is shown in parentheses.

286 **Figure 3.** Individual opioid percent change as reported by the Drug Enforcement Administration's
287 Automated Reports and Consolidated Ordering System (ARCOS) between 2012 and 2019. Changes of
288 greater than +50% are shown in green and greater than -50% in red.

289 **Figure 4.** Hospital-distributed opioid weights per person per state as reported by the Drug Enforcement
290 Administration's Automated Reports and Consolidated Ordering System (ARCOS) in milligrams in 2019.
291 Average opioid weight per person was 17.91mg, standard deviation was 6.92mg. States with opioid
292 weights per person of over 24.84mg were one standard deviation above the average weight and are
293 colored green. States with opioid weights per person of under 10.98mg were one standard deviation
294 below the average weight and are colored red. States with an opioid weight per person that were
295 calculated to be outliers are marked with asterisks ($p < .05$) and include Alaska, Montana, Colorado, and
296 North Dakota.

297 **Figure 5.** Hospital-distributed opioid weights as reported by the Drug Enforcement Administration's
298 Automated Reports and Consolidated Ordering System (ARCOS) in milligrams per person per state in
299 2019.

300 **Figure 6.** Hospital-distributed opioid weights as reported by the Drug Enforcement Administration's
301 Automated Reports and Consolidated Ordering System (ARCOS) in milligrams per person per state in
302 2012.

303 **Figure 7.** Percent decrease in hospital-distributed opioid weights as reported by the Drug Enforcement
304 Administration's Automated Reports and Consolidated Ordering System (ARCOS) per person per state in
305 milligrams from 2012 to 2019. Average decrease in opioid weight per person was -51.38%, and the
306 standard deviation was 9.34%. States with decreases in opioid distributions per person of more than -
307 69.68% were one standard deviation beyond the average decrease and shown in green. States with
308 decreases in opioid distributions per person of under -33.08% were one standard deviation below the
309 average decrease and are shown in red. States with a decrease in opioid distribution per person that
310 were calculated to be outliers are marked with asterisks ($p < .05$).

311


312

313

314


315

316 **Figure 1.** Total opioid distribution in morphine milligram equivalents (MME) in kilograms from 2001 to
317 2019 as reported by the Drug Enforcement Administration's Automated Reports and Consolidated
318 Orders System to hospitals for buprenorphine, codeine, fentanyl, hydrocodone, hydromorphone,
319 meperidine, methadone, morphine, oxycodone, oxymorphone, and tapentadol (black) or with
320 buprenorphine removed (blue).



321
322
323
324
325
326
327

328 **Figure 2.** Individual opioid weights (kg) distributed to US hospitals as reported by the Drug Enforcement
329 Administration's Automated Reports and Consolidated Ordering System (ARCOS) from 2001 to 2018.
330 The percent change relative to the peak year is shown in parentheses.



331

332

333

334


335

336

337

338


339 **Figure 3.** Individual opioid percent change as reported by the Drug Enforcement Administration's
340 Automated Reports and Consolidated Ordering System (ARCOS) between 2012 and 2019. Changes of
341 greater than +50% are shown in green and greater than -50% are shown in red.



342

343


344 **Figure 4.** Hospital-distributed opioid weights per person per state as reported by the Drug Enforcement
345 Administration's Automated Reports and Consolidated Ordering System (ARCOS) in milligrams in 2019.
346 Average opioid weight per person was 17.91 mg, standard deviation was 6.92 mg. States with opioid
347 weights per person of over 24.84 mg were one standard deviation above the average weight and are
348 colored green. States with opioid weights per person of under 10.98 mg were one standard deviation
349 below the average weight and shown in red. States with an opioid weight per person that were outliers
350 are marked with an asterisk ($p < .05$).



351

352

353 **Figure 5.** Hospital-distributed opioid weights as reported by the Drug Enforcement Administration's
354 Automated Reports and Consolidated Ordering System (ARCOS) in milligrams per person per state in
355 2019.



356

357

358

359

360


361

362

363

364

365 **Figure 6.** Hospital-distributed opioid weights as reported by the Drug Enforcement Administration's
366 Automated Reports and Consolidated Ordering System (ARCOS) in milligrams per person per state in
367 2012.



368

369

370

371

372

373

374

375

376

377 **Figure 7.** Percent decrease in hospital-distributed opioid weights as reported by the Drug Enforcement
378 Administration's Automated Reports and Consolidated Ordering System (ARCOS) per person per state in
379 milligrams from 2012 to 2019. Average decrease in opioid weight per person was -51.38%, and the
380 standard deviation was 9.34%. States with decreases in opioid distributions per person of more than -
381 69.68% were one standard deviation beyond the average decrease and shown in green. States with
382 decreases in opioid distributions per person of under -33.08% were one standard deviation below the
383 average decrease and are shown in red. States with a decrease in opioid distribution per person that
384 were outliers are marked with an asterisk ($p < .05$).

